Index
RUT
Market Cap
167.29M
Enterprise Value
-49.55M
Income
-109.52M
Sales
0.00M
Book/sh
5.32
Cash/sh
4.97
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
59
IPO
Feb 07, 2025
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.70
P/C
0.74
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
13.92
Current Ratio
13.92
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-2.43
EPS next Y
-2.39
EPS next Q
-0.61
EPS this Y
-36.99%
EPS next Y
7.17%
EPS next 5Y
-11.48%
EPS past 3/5Y
-22.66% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-52.03%
Sales Y/Y TTM
-
EPS Q/Q
-57.22%
Sales Q/Q
-
Insider Own
47.89%
Insider Trans
-17.04%
Inst Own
71.46%
Inst Trans
12.39%
ROA
-36.35%
ROE
-38.96%
ROIC
-44.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-2.50%
SMA50
-27.73%
SMA200
-87.15%
Trades
Shs Outstand
45.21M
Shs Float
23.56M
52W High
54.97 -93.27%
52W Low
3.19 15.99%
Volatility
10.59% 8.70%
ATR (14)
0.40
RSI (14)
36.65
Beta
1.26
Rel Volume
0.42
Avg Volume
2.29M
Volume
954,720
Perf Week
1.37%
Perf Month
-21.11%
Perf Quarter
-40.80%
Perf Half Y
-90.96%
Perf YTD
-91.01%
Perf Year
-89.66%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
3.57
Price
3.70
Change %
3.64%
Analysts 8 incl. previous ratings
Rating Distribution 1 Buy · 7 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Aug 10, 2026 Upgrade R RBC Capital Mkts
Underperform → Sector Perform $5 +35.1% Aug 10, 2026 Downgrade W Wedbush
Outperform → Neutral $5 +35.1% Aug 10, 2026 Downgrade S Stifel
Buy → Hold $7 +89.2% Aug 10, 2026 Downgrade R Raymond James
Strong Buy → Mkt Perform Aug 10, 2026 Downgrade G Guggenheim
Buy → Neutral Aug 10, 2026 Downgrade C Citizens
Mkt Outperform → Mkt Perform Aug 10, 2026 Downgrade B BTIG Research
Buy → Neutral May 05, 2026 Initiated W Wedbush
Outperform $53 +1,332.4% Feb 24, 2026 Initiated C Citizens
Mkt Outperform $63 +1,602.7% Dec 01, 2025 Downgrade R RBC Capital Mkts
Sector Perform → Underperform $24 +548.6% Nov 19, 2025 Initiated B BTIG Research
Buy $50 +1,251.4% Sep 03, 2025 Initiated R RBC Capital Mkts
Sector Perform $22 +494.6% Sep 03, 2025 Initiated R Raymond James
Strong Buy $45 +1,116.2% Mar 04, 2025 Initiated T TD Cowen
Buy Mar 04, 2025 Initiated S Stifel
Buy $32 +764.9% Mar 04, 2025 Initiated G Guggenheim
Buy $45 +1,116.2%
Show Previous Ratings
Today 07:00AM
Nov-02-26 08:00AM
Oct-08-26 04:30PM
Sep-21-26 05:06PM
Sep-15-26 01:13PM
04:01PM
Loading…
Sep-14-26 04:01PM
Aug-19-26 10:22PM
(PR Newswire)
+5.22%
-11.68%
Aug-17-26 04:20PM
Aug-11-26 09:11AM
Aug-10-26 04:36PM
03:14PM
01:18PM
11:55AM
10:52AM
(The Wall Street Journal)
08:48AM
08:25AM
Loading…
08:25AM
07:00AM
Aug-06-26 07:00AM
May-27-26 08:00AM
May-13-26 08:00AM
May-12-26 07:00AM
Apr-27-26 07:00AM
Apr-07-26 07:00AM
Mar-02-26 07:00AM
Feb-23-26 08:00AM
Feb-15-26 04:41AM
Feb-04-26 07:00AM
Jan-05-26 07:00AM
Dec-23-25 09:33AM
Nov-24-25 07:00AM
06:00PM
Loading…
Nov-14-25 06:00PM
Nov-05-25 07:00AM
Nov-04-25 08:00AM
Oct-31-25 05:42PM
Oct-24-25 01:15PM
Oct-21-25 07:00AM
Oct-01-25 04:05PM
Sep-15-25 12:00PM
Sep-09-25 09:55AM
Sep-08-25 08:00AM
Aug-27-25 07:00AM
Aug-25-25 07:00AM
Aug-11-25 07:00AM
Jun-06-25 11:00AM
Jun-04-25 01:54PM
07:00AM
Jun-03-25 07:00AM
May-22-25 07:00AM
May-12-25 07:00AM
Apr-30-25 07:00AM
Mar-20-25 07:00AM
Mar-15-25 04:43PM
Mar-06-25 10:25AM
Mar-03-25 12:57PM
Feb-25-25 05:56AM
(Pharmaceutical Technology)
-13.37%
Feb-24-25 08:00AM
Feb-17-25 04:43PM
Feb-10-25 04:03PM
(GlobeNewswire)
-11.04%
-8.23%
Feb-06-25 07:51PM
03:13PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Sep 17 '26 Sale 6.33 3,448,811 21,835,018 3,448,812 Sep 21 06:56 PM RA Capital Healthcare Fund, L. Director Sep 17 '26 Proposed Sale 6.33 3,448,811 21,834,318 Sep 17 05:10 PM Thompson Peter A. Director Jul 07 '26 Sale 44.86 85,918 3,854,281 2,469,959 Jul 09 04:47 PM ORBIMED ADVISORS LLC Director Jul 07 '26 Sale 44.86 85,918 3,854,281 2,469,959 Jul 09 04:44 PM Fitzpatrick Jennifer Chief Legal Officer Jul 06 '26 Option Exercise 6.11 10,250 62,628 10,250 Jul 07 04:38 PM Fitzpatrick Jennifer Chief Legal Officer Jul 06 '26 Sale 43.60 10,250 446,862 0 Jul 07 04:38 PM JENNIFER FITZPATRICK Officer Jul 06 '26 Proposed Sale 43.99 10,250 450,898 Jul 06 04:39 PM Thompson Peter A. Director Jun 30 '26 Sale 45.50 115,844 5,270,902 2,555,877 Jul 02 04:45 PM ORBIMED ADVISORS LLC Director Jun 30 '26 Sale 45.50 115,844 5,270,902 2,555,877 Jul 02 04:42 PM Thompson Peter A. Director May 27 '26 Sale 44.49 101 4,493 2,671,721 May 29 09:02 PM ORBIMED ADVISORS LLC Director May 27 '26 Sale 44.49 101 4,493 2,671,721 May 29 08:57 PM OrbiMed Private Investments VI Shareholder May 29 '26 Proposed Sale 42.80 1,082,480 46,330,144 May 29 06:44 PM Thompson Peter A. Director May 11 '26 Sale 46.22 184,639 8,534,015 2,671,822 May 11 07:14 PM Thompson Peter A. Director May 08 '26 Sale 44.58 59,767 2,664,413 2,856,461 May 11 07:14 PM Thompson Peter A. Director May 07 '26 Sale 44.61 48,546 2,165,637 2,916,228 May 11 07:14 PM ORBIMED ADVISORS LLC Director May 11 '26 Sale 46.22 184,639 8,534,015 2,671,822 May 11 06:58 PM ORBIMED ADVISORS LLC Director May 08 '26 Sale 44.58 59,767 2,664,413 2,856,461 May 11 06:58 PM ORBIMED ADVISORS LLC Director May 07 '26 Sale 44.61 48,546 2,165,637 2,916,228 May 11 06:58 PM Thompson Peter A. Director Apr 17 '26 Sale 44.68 52,397 2,341,098 2,967,722 Apr 21 08:42 PM Thompson Peter A. Director Apr 18 '26 Sale 44.52 2,948 131,245 2,964,774 Apr 21 08:42 PM ORBIMED ADVISORS LLC Director Apr 17 '26 Sale 44.68 52,397 2,341,098 2,967,722 Apr 21 08:40 PM ORBIMED ADVISORS LLC Director Apr 18 '26 Sale 44.52 2,948 131,245 2,964,774 Apr 21 08:40 PM Thompson Peter A. Director Apr 15 '26 Sale 44.64 235,863 10,528,924 3,247,025 Apr 16 07:15 PM Thompson Peter A. Director Apr 16 '26 Sale 45.34 226,906 10,287,918 3,020,119 Apr 16 07:15 PM Thompson Peter A. Director Apr 14 '26 Sale 44.51 47,814 2,128,201 3,482,888 Apr 16 07:15 PM ORBIMED ADVISORS LLC Director Apr 15 '26 Sale 44.64 235,863 10,528,924 3,247,025 Apr 16 07:03 PM ORBIMED ADVISORS LLC Director Apr 16 '26 Sale 45.34 226,906 10,287,918 3,020,119 Apr 16 07:03 PM ORBIMED ADVISORS LLC Director Apr 14 '26 Sale 44.51 47,814 2,128,201 3,482,888 Apr 16 07:03 PM Fitzpatrick Jennifer Chief Legal Officer Mar 05 '26 Option Exercise 6.11 10,250 62,628 10,250 Mar 06 06:56 PM Fitzpatrick Jennifer Chief Legal Officer Mar 05 '26 Sale 33.86 10,250 347,019 0 Mar 06 06:56 PM JENNIFER FITZPATRICK Officer Mar 05 '26 Proposed Sale 34.57 10,250 354,342 Mar 05 04:28 PM Thompson Peter A. Director Feb 03 '26 Sale 44.58 29,063 1,295,629 3,530,702 Feb 04 07:43 PM Thompson Peter A. Director Feb 02 '26 Sale 44.57 1,890 84,237 3,559,765 Feb 04 07:43 PM ORBIMED ADVISORS LLC Director Feb 03 '26 Sale 44.58 29,063 1,295,629 3,530,702 Feb 04 07:39 PM ORBIMED ADVISORS LLC Director Feb 02 '26 Sale 44.57 1,890 84,237 3,559,765 Feb 04 07:39 PM TPG GP A, LLC 10% Owner Jan 22 '26 Sale 40.00 250,000 10,000,000 6,494,962 Jan 26 05:24 PM Rise Fund Sling, L.P. Stockholder Jan 22 '26 Proposed Sale 41.77 195,667 8,173,011 Jan 22 08:47 PM Rise Fund Sling II, L.P. Stockholder Jan 22 '26 Proposed Sale 41.77 54,333 2,269,489 Jan 22 08:47 PM ORBIMED ADVISORS LLC Director Dec 24 '25 Sale 44.55 33,356 1,486,010 3,561,655 Dec 29 08:44 PM Thompson Peter A. Director Dec 24 '25 Sale 44.55 33,356 1,486,010 3,561,655 Dec 29 08:42 PM ORBIMED ADVISORS LLC Director Dec 17 '25 Sale 44.50 900 40,050 3,595,986 Dec 19 07:29 PM ORBIMED ADVISORS LLC Director Dec 19 '25 Sale 44.49 875 38,929 3,595,011 Dec 19 07:29 PM ORBIMED ADVISORS LLC Director Dec 18 '25 Sale 44.49 100 4,449 3,595,886 Dec 19 07:29 PM Thompson Peter A. Director Dec 17 '25 Sale 44.50 900 40,050 3,595,986 Dec 19 07:24 PM Thompson Peter A. Director Dec 19 '25 Sale 44.49 875 38,929 3,595,011 Dec 19 07:24 PM Thompson Peter A. Director Dec 18 '25 Sale 44.49 100 4,449 3,595,886 Dec 19 07:24 PM Fitzpatrick Jennifer Chief Legal Officer Dec 05 '25 Option Exercise 6.11 10,250 62,628 10,250 Dec 09 04:57 PM Fitzpatrick Jennifer Chief Legal Officer Dec 05 '25 Sale 40.52 10,250 415,330 0 Dec 09 04:57 PM JENNIFER R FITZPATRICK Officer Dec 05 '25 Proposed Sale 40.88 10,250 419,020 Dec 05 04:27 PM ORBIMED ADVISORS LLC Director Nov 24 '25 Sale 44.54 94,583 4,212,727 3,610,376 Nov 26 06:45 PM ORBIMED ADVISORS LLC Director Nov 25 '25 Sale 44.60 11,890 530,294 3,598,486 Nov 26 06:45 PM ORBIMED ADVISORS LLC Director Nov 26 '25 Sale 44.49 1,600 71,184 3,596,886 Nov 26 06:45 PM Thompson Peter A. Director Nov 24 '25 Sale 44.54 94,583 4,212,727 3,610,376 Nov 26 06:41 PM Thompson Peter A. Director Nov 25 '25 Sale 44.60 11,890 530,294 3,598,486 Nov 26 06:41 PM Thompson Peter A. Director Nov 26 '25 Sale 44.49 1,600 71,184 3,596,886 Nov 26 06:41 PM OrbiMed Private Investments VI Shareholder Nov 24 '25 Proposed Sale 44.38 1,047,770 46,500,033 Nov 24 08:22 PM RA CAPITAL MANAGEMENT, L.P. Director Nov 21 '25 Sale 39.50 25,183 994,728 159,033 Nov 24 05:43 PM RA CAPITAL MANAGEMENT, L.P. Director Nov 20 '25 Sale 40.13 5,133 205,975 166,642 Nov 24 05:43 PM RA Capital Healthcare Fund LP Director Nov 21 '25 Proposed Sale 43.66 1,210 52,829 Nov 21 04:24 PM RA Capital Nexus Fund III, L.P Director Nov 21 '25 Proposed Sale 43.66 6,440 281,170 Nov 21 04:21 PM RA Capital Nexus Fund, L.P. Director Nov 21 '25 Proposed Sale 43.66 9,924 433,282 Nov 21 04:19 PM BLACKWELL PARTNERS LLC - SERIE Director Nov 21 '25 Proposed Sale 43.66 7,609 332,209 Nov 21 04:17 PM RA Capital Nexus Fund III, L.P Director Nov 20 '25 Proposed Sale 38.94 1,313 51,128 Nov 20 04:40 PM RA Capital Nexus Fund, L.P. Director Nov 20 '25 Proposed Sale 38.94 2,023 78,776 Nov 20 04:35 PM RA Capital Healthcare Fund LP Director Nov 20 '25 Proposed Sale 38.94 246 9,579 Nov 20 04:34 PM BLACKWELL PARTNERS LLC - SERIE Director Nov 20 '25 Proposed Sale 38.94 1,551 60,396 Nov 20 04:30 PM RA CAPITAL MANAGEMENT, L.P. Director Nov 17 '25 Sale 40.59 81,987 3,328,081 184,619 Nov 19 08:43 PM RA CAPITAL MANAGEMENT, L.P. Director Nov 19 '25 Sale 40.01 47,442 1,898,173 168,193 Nov 19 08:43 PM RA CAPITAL MANAGEMENT, L.P. Director Nov 18 '25 Sale 39.57 6,922 273,904 182,527 Nov 19 08:43 PM RA Capital Healthcare Fund LP Director Nov 19 '25 Proposed Sale 39.12 2,278 89,115 Nov 19 05:21 PM BLACKWELL PARTNERS LLC - SERIE Director Nov 19 '25 Proposed Sale 38.41 14,334 550,568 Nov 19 05:16 PM RA Capital Nexus Fund, L.P. Director Nov 19 '25 Proposed Sale 38.41 18,696 718,113 Nov 19 05:10 PM RA Capital Nexus Fund III, L.P Director Nov 19 '25 Proposed Sale 38.41 12,134 466,066 Nov 19 05:04 PM BLACKWELL PARTNERS LLC - SERIE Director Nov 18 '25 Proposed Sale 39.04 2,092 81,671 Nov 18 05:22 PM RA Capital Nexus Fund, L.P. Director Nov 18 '25 Proposed Sale 39.04 2,728 106,501 Nov 18 05:17 PM RA Capital Nexus Fund III, L.P Director Nov 18 '25 Proposed Sale 39.04 1,770 69,100 Nov 18 05:09 PM RA Capital Healthcare Fund LP Director Nov 18 '25 Proposed Sale 39.04 332 12,961 Nov 18 04:58 PM BLACKWELL PARTNERS LLC - SERIE Director Nov 17 '25 Proposed Sale 39.93 24,772 989,146 Nov 17 05:12 PM RA Capital Nexus Fund, L.P. Director Nov 17 '25 Proposed Sale 39.93 32,310 1,290,138 Nov 17 05:04 PM RA Capital Nexus Fund III, L.P Director Nov 17 '25 Proposed Sale 39.93 20,969 837,292 Nov 17 04:56 PM RA Capital Healthcare Fund LP Director Nov 17 '25 Proposed Sale 39.93 3,936 157,164 Nov 17 04:46 PM
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.
President Mr. Michael Cloonan M.B.A.
CFO & Chief Business Officer Ms. Elena H. Ridloff C.F.A.
Co-Founder & Senior VP of Discovery Research Dr. Greg Hurlbut Ph.D.
Co-founder Dr. Mark Munson Ph.D.
Vice President of Information & Technology Mr. Andy Chu